Internal medicine

Receptor

Tyrosine-kinase inhibitor

Disease

Ponatinib

Cancer

Oncology

Intensive care medicine

Imatinib

Nilotinib

Bosutinib

Myeloid leukemia

Dasatinib

Tyrosine kinase

Medicine

Frontiers in Oncology

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near normal life-expectancy. However, since the majority of patients will need to remain on treatment indefinitely, physicians in care of CML patients need be familiar with the indications and toxicities of all approved tyrosine kinase inhibitors (TKI). In clinical practice, there are five TKI (imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) that are available in different scenarios and have distinct safety profiles. Decisions regarding first line treatment must be based on CML risk, comorbidities, and patients expectations. Despite the excellent outcome, half of the patients will eventually fail (due to intolerance or resistance) to first line treatment, with many of them requiring a third or even further lines of therapy. When selecting for such patients, it is essential to distinguish between failure and intolerance to previous TKIs. In the present review, we will address all these issues from a practical point of view

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety